Clinical significance of soluble forms of immune checkpoint molecules in advanced esophageal cancer-Reference-Cited by-同舟云学术

Clinical significance of soluble forms of immune checkpoint molecules in advanced esophageal cancer

Published:2019-05-27 Issue:7 Volume:36 Page:
ISSN:1357-0560
Container-title:Medical Oncology
language:en
Short-container-title:Med Oncol

Author:

Yoshida Juichiro,Ishikawa Takeshi^ORCID,Doi Toshifumi,Ota Takayuki,Yasuda Tomoyo,Okayama Tetsuya,Sakamoto Naoyuki,Inoue Ken,Dohi Osamu,Yoshida Naohisa,Kamada Kazuhiro,Uchiyama Kazuhiko,Takagi Tomohisa,Konishi Hideyuki,Naito Yuji,Itoh Yoshito

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,Hematology,General Medicine

Link

http://link.springer.com/content/pdf/10.1007/s12032-019-1285-x.pdf

Reference38 articles.

1. Fitzmaurice C, Dicker D, Pain A, Hamavid H, Moradi-Lakeh M, MacIntyre MF, et al. The global burden of cancer 2013. JAMA Oncol. 2015;1(4):505–27. https://doi.org/10.1001/jamaoncol.2015.0735 .

2. Rustgi AK, El-Serag HB. Esophageal carcinoma. N Engl J Med. 2014;371(26):2499–509. https://doi.org/10.1056/NEJMra1314530 .

3. Kudo T, Hamamoto Y, Kato K, Ura T, Kojima T, Tsushima T, et al. Nivolumab treatment for oesophageal squamous-cell carcinoma: an open-label, multicentre, phase 2 trial. Lancet Oncol. 2017;18(5):631–9. https://doi.org/10.1016/s1470-2045(17)30181-x .

4. Doi T, Piha-Paul SA, Jalal SI, Saraf S, Lunceford J, Koshiji M, et al. Safety and antitumor activity of the anti-programmed death-1 antibody pembrolizumab in patients with advanced esophageal carcinoma. J Clin Oncol. 2018;36(1):61–7.

5. Masson D, Jarry A, Baury B, Blanchardie P, Laboisse C, Lustenberger P, et al. Overexpression of the CD155 gene in human colorectal carcinoma. Gut. 2001;49(2):236–40.

Cited by 32 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Baseline sLAG-3 levels in Caucasian and African-American breast cancer patients;Breast Cancer Research and Treatment;2024-09-04

2. Soluble immune checkpoint molecules in cancer risk, outcomes prediction, and therapeutic applications;Biomarker Research;2024-09-02

3. A novel enzyme-linked immunosorbent assay tool to evaluate plasma soluble CD226 in primary Sjögren's syndrome;Analytical Biochemistry;2024-09

4. Soluble immune checkpoints: implications for cancer prognosis and response to immune checkpoint therapy and conventional therapies;Journal of Experimental & Clinical Cancer Research;2024-05-31

5. CD155 as an emerging target in tumor immunotherapy;International Immunopharmacology;2024-04